Sumitomo Mitsui DS Asset Management’s NovoCure NVCR Stock Holding History

Sumitomo Mitsui DS Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,233	Closed	-$300K	–	785
2023 Q2	$300K	Hold	7,233	–	–	﹤0.01%	733
2023 Q1	$435K	Hold	7,233	–	–	0.01%	691
2022 Q4	$531K	Hold	7,233	–	–	0.01%	641
2022 Q3	$550K	Buy	7,233 +2,471	+52%	+$193K	0.01%	615
2022 Q2	$331K	Hold	4,762	–	–	0.01%	699
2022 Q1	$395K	Sell	4,762 -50	-1%	-$3.68K	0.01%	693
2021 Q4	$361K	Hold	4,812	–	–	0.01%	713
2021 Q3	$559K	Sell	4,812 -33	-0.7%	-$4.99K	0.01%	638
2021 Q2	$1.07M	Buy	4,845 +3	+0.1%	+$584	0.03%	492
2021 Q1	$640K	Buy	4,842 +40	+0.8%	+$6.33K	0.02%	590
2020 Q4	$830K	Buy	+4,802	New	+$657K	0.02%	509

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Sumitomo Mitsui DS Asset Management's NVCR Position: Q3 2023 in Review

Sumitomo Mitsui DS Asset Management sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 7,233 shares — an estimated $300K sold.

Sumitomo Mitsui DS Asset Management first reported a position in NVCR in Q4 2020 and held it in 11 quarters. The position peaked at $1.07M in Q2 2021. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

Sumitomo Mitsui DS Asset Management reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
Sumitomo Mitsui DS Asset Management sold 7,233 NovoCure shares in Q3 2023, an estimated $300K.
Sumitomo Mitsui DS Asset Management first reported a position in NovoCure in Q4 2020 and held it in 11 quarters.
Sumitomo Mitsui DS Asset Management's NovoCure position peaked at $1.07M in Q2 2021.
226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on Sumitomo Mitsui DS Asset Management's 13F filing for Q3 2023, filed 30 Oct 2023.